Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal) (TA194)
Fast, easy summary view of NICE guidance on 'prostate cancer'
NICE is unable to recommend the use in the NHS of denosumab for the treatment of therapy-induced bone loss in people with non-metastatic prostate cancer because no evidence submission was received from the manufacturer or sponsor of the technology.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: prostate cancer
- None found
This page was last updated: 26 October 2011
Implementation tools and resources
- None available
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.